On 31 May 2024, the European Medicines Agency (EMA) published the Committee for Medicinal Products for Human Use (CHMP) reflection paper on Creutzfeldt-Jakob disease (CJD) and plasma-derived and urine-derived medicinal products.
In the framework of the EU Initiative on Health Security, ECDC and the EU Member States set up an ‘Exchange of Experts’ programme aiming to provide experts from European Neighbourhood Policy (ENP) partner countries with opportunities to learn from the experiences of EU Member States within specific disease areas, and in turn, share their own experiences.
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.